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Abstract

Patients with type-2 diabetes mellitus (T2DM) have normal or increased bone mineral
density (BMD) but despite that, they are characterized by an increased hip and vertebral
fracture risk that involves the alteration of bone quality and not the reduction in bone
mass. BMD is utilized for the diagnosis and evaluation of osteoporosis, but BMD itself
cannot provide an accurate diagnosis of the individuals at increased risk of fracture and,
therefore, studies have focused on identifying other risk factors that are partially or fully
independent of BMD.
The fracture risk score tool-FRAX® models provide information about a 10-year
probability of osteoporotic fractures, but do not include risk factors specific to illness
such as diabetes duration, diabetes drug therapy, glycemic control, or the presence of
micro-vascular complications. Multiple markers have been investigated to provide
information on the risk of fractures in patients with T2DM such as: advanced glycation
end products (AGEs), insulin-like growth factor-I (IGF-I), osteocalcin (OC), adiponectin,
and sclerostin, but epidemiological studies did not provide homogeneous information
regarding the link between these markers and bone fragility in T2DM subjects. Markers
that increase the accuracy of fracture risk estimation in patients with T2DM need to be
identified and employed in current medical practice.
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 Patients with type 2 diabetes mellitus have significantly higher scores in over-vigilance
and inhibition schematic domains.
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 Epidemiological studies do not provide unitary information on the association between
markers of bone fragility and fracture risk in T2DM.
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Introduction
According to the American Diabetes Association,
diabetes is a heterogeneous chronic disease which
includes the following categories: type-1 diabetes
(T1DM) generated by beta-cell destruction; T2DM due to
a progressive loss of beta-cell insulin and insulin
resistance; and gestational diabetes and other types of
diabetes caused by other problems. T2DM represents 9095% of all types of diabetes (1). The International
Diabetes Federation (IDF) estimates the global prevalence
of diabetes in the age group of 20–79 years in 2015 at 415
million, with an uncertainty range of 340–536 million.
For the same group, IDF predicted 642 million with an
unclear range: 521–829 million for 2040 (2). After the
analysis of the published studies, Kaiser AB and coworkers estimate that in 2018 there are more than 500
million cases of T2DM worldwide and this prevalence
will increase (3). In 2018, in Romania the number of
patients with diabetes who underwent treatment was
823,280, out of which 241,600 following insulin therapy
and 581,680 non-insulin agents (4).
Individuals with T2DM present normal ranges or
increased ranges of BMD in comparison with subjects
without diabetes. Despite that, they are characterized by
increased fracture risk caused by the alteration of bone
quality (5). The Rotterdam study evaluated the correlation
between T2DM and fractures in 6,655 men and women
aged 55 years or older compared to subjects without
diabetes. The data from the study show that diabetic
patients had high BMD and increased fracture risks
compared to the control group (6). The observational
study conducted by Leslie WD and co-workers, in which
6,455 diabetic patients and 55,958 subjects without
diabetes were included, has revealed diabetes as an
independent risk factor for major osteoporotic fractures
(7).
The association between the duration of the disease,
glycemic control, the presence of microvascular
complications, and the risk of fracture have been
investigated in several other studies. The Manitoba cohort
which included 57,938 women, 8,840 with diabetes and
49,098 without diabetes, aged 40 years or more, had
highlighted that diabetes is a risk factor for major
osteoporotic fractures only in women who have had the
illness for a long period of time (more than 10 years) (8).
Another study conducted by Leslie WD and collaborators
in which 82,094 diabetic patients and 236,682 nondiabetic subjects were enrolled highlighted that long-term
diabetes is correlated with an increased risk of fractures.
Newly diagnosed patients have a low risk of fractures (9).

The Blue Mountains Eye Study showed that the duration
of diabetes for 10 years or more is associated with
proximal humeral fracture (10). Concerning the glycemic
ranges and fracture risk, in a meta-analysis published in
2007 in Osteoporosis International, Vestergaard P found
no correlation between glycated hemoglobin (HbA1) and
BMD (11). In contrast, other studies support the
association between increased fracture risk and poor
glucose control (12, 13). Patients with T2DM and
microvascular disease have a compromised cortical bone
microarchitecture via an increase in cortical porosity (14).
BMD is utilized in the diagnosis and evaluation of
osteoporosis, and the most used and validated technique
for determining BMD is dual energy X-ray
absorptiometry (DEXA). The international reference for
the diagnosis of osteoporosis is a T-score equal to or
lower than -2.5 standard deviation (SD) at the lumbar
spine or femoral neck and osteopenia as a T-score
between -1.0 SD and -2.5 SD (15, 16). BMD itself cannot
provide a good estimation of the individuals at higher risk
of fracture. Therefore studies have focused on identifying
other risk factors that are partially or fully independent of
BMD. The FRAX® models provide information about a
10-year probability of osteoporotic fractures, with and
without BMD at the femoral neck (16).
There is a variant in the Romanian language
version, which includes 12 items: age/sex/height(cm)
/weight(kg), fracture history, parental hip fracture,
active smoking, glucocorticoid therapy, rheumatoid
arthritis, secondary osteoporosis, minimal alcohol 3
U/day, and BMD at the femoral neck. The item on
secondary osteoporosis only mentions insulindependent type-1 diabetes mellitus (T1DM) and not
T2DM. T2DM represents a risk factor that is
independent of conventional risk factors. For this
reason Ferrari SL and collaborators proposed the
following risk factors specific to the illness: diabetic
age.> 5 years, diabetic drug therapy (insulin,
thiazolidinedione, sodium-glucose co-transporter 2SGLT2 inhibitors), HbA1c.>7%, micro-vascular
complications (17). The results of two studies
published in 2012 in the Journal of Bone and Mineral
Research suggest the inclusion of diabetes in future
iterations of FRAX® (18, 19).
Serum potential markers for bone fragility in
patients with T2DM
Multiple serum markers have been investigated to
provide information on the risk of fractures in patients
with T2DM. Serum indicators of bone turnover include
bone formation markers produced by direct or indirect

79

Markers of Bone Fragility in Type-2 Diabetes
osteoblasts activity, resorption markers which are derived
from the skeletal collagen and other indicators.
Bone formation indicator consists of osteocalcin,
alkaline phosphatase, bone-specific alkaline phosphatase,
procollagen type 1 amino terminal pro-peptide (P1NP),
procollagen type 1 carboxy-terminal pro-peptide (P1CP),
and osteoprotegerin (20).
Osteocalcin is a protein secreted by osteoblasts. It is
considered a marker of bone formation, but osteocalcin
also has metabolic effects. Studies on animal models have
shown that osteocalcin has a positive impact on insulin
expression in beta-cells and adiponectin in adipocytes (21,
22). Clinical trials confirmed the correlation between
osteocalcin, glucose and adiponectin levels - osteocalcin
was negatively correlated with plasma glucose levels and
positively correlated with serum adiponectin and insulin
sensitivity [23, 24, 25]. Hyperglycemia alters osteocalcin
secretion and glycemic control improves the osteocalcin
level [26]. Adiponectin is expressed in bone marrow fat.
Osteoblastic cells have adiponectin receptors and
adiponectin
participates
in
the
differentiation,
proliferation and mineralization of osteoblasts (27, 28).
Alkaline phosphatase is an enzyme highly expressed
in bone, liver, and kidney. Increased serum alkaline
phosphatase levels are found throughout bone growth, in
the liver and in bone diseases. Alkaline phosphatase is an
inflammatory mediator and previous works have shown
an association between alkaline phosphatase levels and
cardiovascular events (29, 30). The results of studies on
alkaline phosphatase levels in diabetic patients are
contradictory. Studies highlighted that diabetic patients
have a lower, similar or an increased serum alkaline
phosphatase level compared to the control group. In a
prospective study, Dutta MK and collaborators have
evaluated alkaline phosphatase levels in 67 patients with
T2DM and 137 nondiabetic subjects. The mean alkaline
phosphatase levels were lower with statistical significance
in diabetic patients compared to the control group (88.5 ±
33.3 U/l vs 214.7 ± 59.7 U/l, p ˂ 0.00001) and the authors
suggested that the low levels of alkaline phosphatase
reflect a decreased bone turnover and increased osteoclast
genesis (31). Akin O et al report similar values of alkaline
phosphatase concentration in a study group and a control
group, while other researchers have highlighted that the
mean serum level of alkaline phosphatase in diabetic
patients with poor glycemic control is significantly higher
compared to healthy controlled subjects (29, 32). Bone
alkaline phosphatase is one of the isoforms of the alkaline
phosphatase on the surface of osteoblasts and it is an
indicator of osteoblast metabolism (33). Insufficient
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studies are available to establish the correlation between
bone alkaline phosphatase and the risk of fractures in
T2DM patients. The “Japanese Population-based
Osteoporosis Cohort Study” evaluated bone alkaline
phosphatase in 522 postmenopausal women without
illness or treatment affecting bone metabolism. The
results of the study revealed that bone alkaline
phosphatase was correlated with a risk of vertebral
fractures in the patients included in the survey (34). In a
cross-sectional study in which 143 diabetic patients and
4.054 subjects without diabetes were enrolled no
differences were found in bone alkaline phosphatase
between the two groups (33).
Type 1 pro-collagen is synthesized and secreted in the
bone matrix. At this level, pro-collagen peptidases cut
P1NP from the amino-terminal end and P1CP from the
carboxy-terminal end, resulting in mature type 1 collagen.
(35). P1NP and P1CP are standard bone formation
markers but not currently included in the assessment of
fracture risks as well as other markers of bone turnover
due to the lack of conclusive information (36). In a crosssectional study in which 155 healthy subjects were
included, P1NP was inversely correlated with insulin and
glucose levels (37). In another study in which 183
postmenopausal females were included, 93 with
osteoporosis (the study group) and 90 without
osteoporosis (the control group), the mean P1NP level
was higher, with statistical significance in the study group
compared to the control group (38). Liu S et al analyzed
the level of P1NP in 76 patients with T2DM (19 with
osteoporosis, 25 with osteopenia, and 32 with preserved
bone mass). The level of P1NP was significantly higher in
T2DM patients with preserved bone mass and osteopenia
than in diabetic patients with osteoporosis (p < 0.05) (39).
A review published in 2017 in the European Journal of
Endocrinology, which included the results of 66 studies,
showed that P1NP levels were lower in patients with
diabetes compared to control groups (40). The assessment
of P1CP levels is increased in subjects with T2DM and it
is an indicator for the diastolic dysfunction and
progression of diabetic nephropathy (41, 42).
Bone resorptive markers are represented by aminoterminal cross-linked telo-peptide of type-I collagen
(NTX), carboxy-terminal cross-linked telopeptide of typeI collagen (CTX), tartrate-resistant acid phosphatase 5b
(TRAP), receptor activator of nuclear factor kappa beta
ligand (RANKL), pyridinoline, deoxypyridinoline,
hydroxyproline (20).
The evaluation of bone resorptive markers provides
inconsistent results about the association of these markers
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with diabetes. The “Fremantle Diabetes Study” revealed
higher CTX levels in T1DM male patients (43). A crosssectional study evaluated bone resorption markers (CTX
and TRAP) in 78 T2DM patients compared to 55 subjects
without diabetes. T2DM patients have decreased levels of
bone resorptive markers compared to control patients
(44). Osteoblast cells express RANKL which bind to their
RANK receptor on the surface of osteoclasts and
stimulate the differentiation of precursors in mature
osteoclasts. Osteoprotegerin is secreted by osteoblasts and
protects the skeletal system from exacerbated bone
resorption by interacting with RANKL and preventing it
from binding to RANK (45). Alteration of the
RANKL/osteoprotegerin pathways have been involved in
metabolic bone disease, vascular calcification and
atherogenesis (46). Epidemiological studies do not
provide homogeneous information on RANKL and
osteoprotegerin levels in diabetic patients. A case-control
study evaluated RANKL, osteoprotegerin levels in 42
women (21 women with T2DM and 21 women without
diabetes). The authors found decreased levels of RANKL
in the study group compared to the control cohort; the
osteoprotegerin levels were not significantly different
between the groups (47). Lappin DF et al evaluated
plasma levels of bone markers in 63 patients with T1DM
and 38 control subjects. T1DM patients had significantly
decreased RANKL levels and increased osteoprotegerin
compared to the control group (48). In contrast, increased
levels of RANKL and increased osteoprotegerin were
found in 40 young patients with T1DM compared to 40
healthy control subjects (49).
Other studied serum markers of bone fragility in
diabetes are AGEs, IGF-I, and sclerostin.
AGEs are formed by the non-enzymatic glycoxidation
of the protein-amino group. AGEs accumulate in tissues
and are involved in the occurrence of the chronic
complications of diabetes. The receptors for AGEs are
expressed in the human bone and their activation
generates synthesis inhibition of type 1 collagen and
osteocalcin (50, 51). Thus, AGEs generate osteoblastic
dysfunction and increased osteoclast activity (52, 53).
One of the AGEs is characterized by pentosidine.
Pentosidine content in cortical or trabecular bone was
associated with the deterioration of bone quality (54, 55).
Yamamoto T and coworkers have investigated the
correlation between serum pentosidine concentration and
vertebral fractures in 77 men and 76 postmenopausal
women with T2DM. The authors conclude that
pentosidine concentration is correlated with vertebral
fractures in postmenopausal diabetic women, independent

of BMD (56). In a multi-center study in which 271
nondiabetic patients with osteoporosis were included,
urinary pentosidine levels at baseline were increased and
predicted vertebral fractures under bisphosphonate
therapy (57). A cohort study conducted by Schwartz AV
highlighted that urine pentosidine concentrations were
higher in older individuals with T2DM and predict future
facture (58).
Bone mass is regulated by hormones and local factors;
IGF-I is synthesized in the liver and osteoblasts and exerts
the anabolic effects of bone. Experimental studies
highlighted that IGF-I stimulates the synthesis of
deoxyribonucleic acid, collagen, and non-collagenous
protein; reduce collagen degradation in bone cell cultures;
and is essential in bone matrix mineralization (59, 60).
Increased levels of glucose and AGEs decrease the
proliferative response of osteoblastic cell to IGF-I and
secretion of IGF-I by osteoblasts (61, 62). Clinical studies
show that free and total IGF-I are lower in patients with
osteoporosis compared to controls (63, 64). Few clinical
trials have investigated the relationship between IGF-I
levels and bone metabolism in patients with T2DM.
Miyake H and collaborators followed the association
between IGF-I levels and the occurrence of non-vertebral
osteoporotic fractures in 356 patients with T2DM (168
postmenopausal women and 188 men). Their results
showed that decreased IGF-I concentration is correlated
with an increased occurrence of non-vertebral
osteoporotic fractures in postmenopausal women with
T2DM (65). In 2007 and 2011, Kanazawa I et al
published two studies about the association between IGFI concentration and occurrence/severity of vertebral
fractures in postmenopausal women with T2DM in
Osteoporosis International. In the first study, they
included 131 postmenopausal women with T2DM and the
results showed that IGF-I levels were significantly
decreased in women with vertebral fractures compared to
women without fractures (66). In the second study, 813
patients with T2DM (334 postmenopausal women and
479 men) were recruited. In postmenopausal women,
decreased IGF-I levels have been confirmed to be
correlated with the number of vertebral fractures; in men,
no association between IGF-I level and vertebral fractures
was observed (67). The mechanism that associated
changes of IGF levels in osteoporosis remains unclear,
but IGF-I levels may predict fractures.
Sclerostin is a tiny protein produced by osteocytes and
it has an anti-anabolic effect on bone formation (68). A
study that included 74 patients with T2DM highlighted
that circulating concentrations of sclerostin are higher in
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individuals with T2DM than in the control group (50
subjects) and sclerostin levels were positively correlated
with the duration of diabetes and HbA1c (69). Similar
results, respectively significantly increased sclerostin
levels in patients with T2DM versus control groups, have
been reported by Khalek MAA and collaborators (70).

Conclusion
Subjects with T2DM have normal or increased BMD
compared to subjects without diabetes, yet despite this,
they are characterized by increased fracture risk that
involves the alteration of bone quality. BMD is used in
the diagnosis and evaluation of osteoporosis, but BMD
itself cannot provide an optimal diagnosis in the detection
of patients with high-risk fractures; therefore, surveys
have focused on identifying other risk factors that are
partially or fully independent of BMD. The FRAX®
models provide information about a 10-year probability of
osteoporotic fractures, but do not include risk factors
specific to the illness such as: diabetes duration, diabetes
drug therapy, glycemic control or the presence of
microvascular complications. Epidemiological studies do
not provide unitary information on the association
between markers of bone fragility and fracture risk in
T2DM. Markers that increase the accuracy of fracture risk
estimated in patients with T2DM must be identified and
used in current medical practice.
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